PMID: 6537919Jan 1, 1984Paper

The effects of tubulazole, a new synthetic microtubule inhibitor on experimental neoplasms

European Journal of Cancer & Clinical Oncology
R Van GinckelJ Heeres

Abstract

Tubulazole, a new synthetic microtubule inhibitor in vitro, is tested in vivo upon three experimental neoplasms: MO4 sarcoma, L1210 leukemia and TA3 carcinoma. The compound is tested using different treatment schedules upon different inoculation routes of the cells. All trials show the compound to have distinct antineoplastic properties in vivo by prolonging the median survival time. The best treatment schedule seems to be an intermittent one, i.e. treatment every fourth day starting 1 day after tumor inoculation. Comparison with cyclophosphamide and vincristine is in favor of tubulazole for treating TA3 mammacarcinoma, while cyclophosphamide and vincristine give somewhat better results upon L1210 leukemia. The effects of tubulazole and cyclophosphamide upon MO4 fibrosarcoma are comparable, while vincristine has no effect in this system. Worthwhile noting is that all the in vivo, as well as in vitro, activity of tubulazole resides in the cis isomer, while the trans isomer has no effect at all.

References

Sep 1, 1975·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Atassi, H J Tagnon

❮ Previous
Next ❯

Citations

Jan 1, 1986·Annals of the New York Academy of Sciences·M De BrabanderM Mareel
May 1, 1992·Medical & Biological Engineering & Computing·L Vodovnik, R Karba
Jan 1, 1989·Critical Reviews in Oncology/hematology·M M Mareel, M De Mets

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinosarcoma

Carcinosarcoma is a malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. Discover the latest research on carcinosarcoma here.